Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

Blood (2024) 144 (Supplement 1): 1839.

https://doi.org/10.1182/blood-2024-201317

Published: 2024

Journal Articles

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Blood (2021) 138 (Supplement 1): 63.

https://doi.org/10.1182/blood-2021-147898

Published: 2021

Journal Articles

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

Blood (2021) 138 (Supplement 1): 3697.

https://doi.org/10.1182/blood-2021-150904

Published: 2021

Journal Articles

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

Cecile Tomowiak, MD, Kristell Desseaux, Stéphanie Poulain, MD PhD, Charles Herbaux, MD, Aurore Perrot, MD PhD, Beatrice Mahe, MD, Pierre Morel, MD, Olivier Tournilhac, Stephane Lepretre, MD, Thérèse Aurran, MD, Bruno Villemagne, MD, Olivier Casasnovas, MD, Delphine Nollet, Brigitte Dreyfus, MD, Sylvie Chevret, MD PhD, Veronique Leblond, MD PhD

Blood (2019) 134 (Supplement_1): 346.

https://doi.org/10.1182/blood-2019-122826

Published: 2019

Journal Articles

A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, MD PhD, Agnes Guerci-Bresler, MD, Pascale Cony-Makhoul, MD, Laurence Legros, MD, Marie Sebert, MD, Thorsten Braun, MD PhD, Jacques Delaunay, MD, Benedicte Samey, Kristell Desseaux, Sylvie Chevret, Pierre Fenaux, MD PhD

Blood (2015) 126 (23): 2869.

https://doi.org/10.1182/blood.V126.23.2869.2869

Published: 2015

Journal Articles

A Phase II Study Of The Efficacy and Safety Of An Intensified Schedule Of Azacitidine (AZA) In Intermediate-2 and High Risk MDS Patients

Lionel Ades, Agnès Guerci-Bresler, MD, PhD, Pascale Cony Makhoul, Laurence Legros, MD, PhD, Jacques Delaunay, MD, Christian Recher, MD PhD, Kristell Desseaux, Benedicte Samey, Sylvie Chevret, Pierre Fenaux, MD, PhD

Blood (2013) 122 (21): 1513.

https://doi.org/10.1182/blood.V122.21.1513.1513

Published: 2013

Journal Articles

Single Versus Tandem High Dose Therapy (HDT) Supported with Autologous Blood Stem Cell (ABSC) Transplantation Using Unselected or CD34-Enriched ABSC: Long-Term Results of a Two by Two Designed Randomized Trial in 225 Young Patients with Multiple Myeloma (MM). for the Group “Myelome-Autogreffe”, Caen, Creteil, Limoges, Paris, Strasbourg, France.

Jean-Paul Fermand, Kristell Desseaux, Jean Pierre Marolleau, MD

Blood (2009) 114 (22): 2320.

https://doi.org/10.1182/blood.V114.22.2320.2320

Published: 2009

NARROW

Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM)

A Phase II Study Of The Efficacy and Safety Of An Intensified Schedule Of Azacitidine (AZA) In Intermediate-2 and High Risk MDS Patients

Email alerts

ASH Publications

American Society of Hematology

Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM)

A Phase II Study Of The Efficacy and Safety Of An Intensified Schedule Of Azacitidine (AZA) In Intermediate-2 and High Risk MDS Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only